HC Wainwright Weighs in on Unity Biotechnology, Inc.’s Q1 2024 Earnings (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – Analysts at HC Wainwright issued their Q1 2024 EPS estimates for Unity Biotechnology in a report released on Tuesday, April 16th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.57) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.

Unity Biotechnology Stock Down 1.0 %

Shares of NASDAQ:UBX traded down $0.02 during trading on Wednesday, reaching $1.51. 28,480 shares of the company traded hands, compared to its average volume of 88,311. The firm has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $1.78. The firm has a market cap of $25.25 million, a P/E ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a 1-year low of $1.50 and a 1-year high of $3.82.

Institutional Investors Weigh In On Unity Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP acquired a new position in Unity Biotechnology during the 1st quarter worth $32,000. Virtu Financial LLC lifted its position in Unity Biotechnology by 25.4% during the 2nd quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock worth $35,000 after acquiring an additional 12,681 shares during the last quarter. Jane Street Group LLC acquired a new position in Unity Biotechnology during the 4th quarter worth $37,000. Schonfeld Strategic Advisors LLC acquired a new position in Unity Biotechnology during the 4th quarter worth $38,000. Finally, Commonwealth Equity Services LLC lifted its position in Unity Biotechnology by 53.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock worth $39,000 after acquiring an additional 8,499 shares during the last quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.